BioNexus Gene Lab Corp (BGLC) stock
Close on Nov 11, 2026Market cap $2.52MP/E –Yield –
BioNexus Gene Lab Corp saw revenue fall 67.3% to $3.13M over the twelve months to Jun 30, 2026. Free cash flow was -$853.60K. At the latest close the market valued the company at $2.52M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.52M
- P/E ratio
- –
- Price to sales
- 0.81
- Price to book
- 0.32
- Dividend yield
- –
- Free cash flow yield
- -33.88%
Fundamentals
- Revenue
- $3.13M
- Net income
- -$2.58M
- Free cash flow
- -$853.60K
- Book value per share
- $3.22
- Diluted shares
- 2M
Trading
- Previous close
- $0.82
- Open
- $0.89
- Day's range
- $0.82 – $0.95
- Volume
- 11,675
- Average volume (20 days)
- 5,964
- Beta (5 years)
- 0.88
- 52-week range
- $0.81 – $5.15
- RSI (14 days)
- 33.4
- Volatility (1 year)
- 70.9%
- Relative volume
- 1.18×
- WACC
- 9.3%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BGLC | S&P 500 | Difference | BGLC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -33.4% | -2.4% | −31.0 pts | ||
| 3 months | -43.5% | -1.2% | −42.3 pts | ||
| Year to date | -78.3% | +12.3% | −90.5 pts | ||
| 1 year | -83.3% | +12.4% | −95.8 pts | ||
| 3 years | -74.0% | +78.8% | −152.8 pts | -36.2% | +21.4% |
| 5 years | -99.6% | +75.2% | −174.8 pts | -67.4% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioNexus Gene Lab filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- Update
- News
- News
About BioNexus Gene Lab
Services-Medical Laboratories
BioNexus Gene Lab Corp. operates in chemical raw material distribution and genomic testing through its operating subsidiaries. The company wholesales chemical raw materials, primarily fiber-reinforced polymers and polyester resins, serving manufacturers, fabricators, and contractors across the industrial, automotive, aerospace, medical, appliance, and electronic sectors. It also provides blood-based genomic screening services and laboratory analysis that assess ribonucleic acid changes to evaluate risk for cancers, inflammatory bowel diseases, osteoarthritis, and cardiovascular conditions, delivering risk analysis reports to referring doctors, clinics, and hospitals.
Company profile, executives and historyBioNexus Gene Lab stock: common questions
What is BioNexus Gene Lab's stock price?
BGLC closed at $0.86 on Nov 11, 2026, up 4.74% on the day. Over the past 52 weeks it traded between $0.81 and $5.15.
What is BioNexus Gene Lab's market cap?
BioNexus Gene Lab was worth $2.52M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does BioNexus Gene Lab make?
BioNexus Gene Lab reported revenue of $3.13M for the twelve months to Jun 30, 2026, down 67.3% from a year earlier.
Does BioNexus Gene Lab pay a dividend?
No. BioNexus Gene Lab has not paid a cash dividend over the last twelve months.
How has BGLC stock performed over the past year?
Including dividends, BGLC returned -83.3% over the past year, against +12.4% for the S&P 500.
How many BGLC shares are sold short?
0M shares were sold short at the latest FINRA report, 0.16% of the float, or 1.0 days of average trading volume.
Who are BioNexus Gene Lab's competitors?
Companies most similar to BioNexus Gene Lab by business, industry and size include ALPS, YDES, XGN, EUDA, PSNL.
See a number that looks wrong?